Clinical Trial: A Two Part Dose-escalation Safety and Efficacy Study of CID-103 in Adults With Active and Chronic Active Renal Allograft Antibody Mediated Rejection (ABMR).

U.S., June 12 -- ClinicalTrials.gov registry received information related to the study (NCT07641426) titled 'A Two Part Dose-escalation Safety and Efficacy Study of CID-103 in Adults With Active and Chronic Active Renal Allograft Antibody Mediated Rejection (ABMR).' on May 20.

Brief Summary: The goal of the global Phase 1/2 clinical trial is to evaluate whether CID-103, a novel anti-CD38 monoclonal antibody, is safe and effective in adults with with active and chronic active renal allograft antibody mediated rejection (ABMR). The main questions the study aims to answer are:* To evaluate the safety and tolerability of CID-103 in subjects with ABMR with different increasing doses of CID-103.* To evaluate clinical efficacy of CID-103 at an op...